GGrantIndex
Sort

51,570 grants matching autoimmune disease

Hormone, cytokine, and genetic risks for RA in women

$518,211
Elizabeth W Karlson · Brigham And Women'S Hospital · R01 · FY2006 · AR

A TCF1:Glucocorticoid regulatory circuit controls IL-23-driven Th17 pathogenicity

$518,040
Ana C Anderson · Brigham And Women'S Hospital · R01 · FY2023 · AI

Inflammation, Macrophage Differentiation, and Cancer

$517,920
Zheng-Gang Liu · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA

Protein Characterization By Mass Spectrometry

$517,864
Kenneth Tomer · National Institute Of Environmental Health Sciences · ZIA · FY2011 · ES

Molecular and Cellular Immunology

$517,734
Jason G. Cyster · University Of California, San Francisco · T32 · FY2021 · AI

Proteomic changes/progression of human type 1 diabetes

$517,676
Jin-Xiong She · Augusta University · R33 · FY2006 · HD

Characterizing the genetic and evolutionary determinants of population variation in transcriptional responses to pathogens

$517,611
Luis Bruno Barreiro · University Of Chicago · R35 · FY2025 · GM

Characterizing the genetic and evolutionary determinants of population variation in transcriptional responses to pathogens

$517,611
Luis Bruno Barreiro · University Of Chicago · R35 · FY2024 · GM

Mediator kinases as interferon antagonists in Down Syndrome

$517,578
Dylan J Taatjes · University Of Colorado · R01 · FY2022 · AI

Mitochondrial DNA Stress Activation of Interferon Signaling and Lupus Pathology

$517,565
Gerald S Shadel · Salk Institute For Biological Studies · R01 · FY2018 · AR

Apoptosis in Sjogrens Syndrome

$517,523
Antony Rosen · Johns Hopkins University · R37 · FY2007 · DE

Engineering and Analysis of T cell CD3 and IL2R Signals

$517,512
Massachusetts Institute Of Technology · R01 · FY2005 · AI

The genetic basis of type 1 diabetes autoimmunity in African Americans

$517,510
Janelle A Noble · Children'S Hospital & Res Ctr At Oakland · R01 · FY2012 · DK

A TCF1:Glucocorticoid regulatory circuit controls IL-23-driven Th17 pathogenicity

$517,503
Ana C Anderson · Brigham And Women'S Hospital · R01 · FY2024 · AI

Complement system and humoral immunity

$517,500
Michael Craig Carroll · Immune Disease Institute, Inc. · R01 · FY2011 · AI

Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease

$517,434
David Oupicky · University Of Nebraska Medical Center · R01 · FY2022 · DK

Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease

$517,434
David Oupicky · University Of Nebraska Medical Center · R01 · FY2020 · DK

Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease

$517,434
David Oupicky · University Of Nebraska Medical Center · R01 · FY2021 · DK

Chloroquine-based polymer particles as oral non-absorbable treatment of inflammatory bowel disease

$517,434
David Oupicky · University Of Nebraska Medical Center · R01 · FY2023 · DK

(PQ8) Patient- and tumor-specific biomarkers and mechanisms that predict irAEs resulting from checkpoint inhibition

$517,415
Justin M Balko · Vanderbilt University Medical Center · R01 · FY2021 · CA

Dissecting transcriptomics and epigenomic signatures of immune cells in type 1 diabetes

$517,339
Golnaz Vahedi · University Of Pennsylvania · U01 · FY2021 · DK

Antibody Mediated Immune Regulation

$517,331
James C. Zimring · Bloodworks · P01 · FY2018 · HL

(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors

$517,329
Anton Wellstein · Georgetown University · R01 · FY2019 · CA

Nanotechnology Enabled Selection of MHC-Peptide Ligands to Personalize Cancer Therapy

$517,321
Georgios Alexandrakis · University Of Texas Arlington · R21 · FY2020 · CA

The role of cytotoxic T cells in rheumatoid arthritis pathogenesis

$517,284
Felipe Andrade · Johns Hopkins University · R01 · FY2025 · AR